

Zimmer Presents Trabecular Metal Technology Experience at AAOS Annual Meeting

Feb 25, 2009

WARSAW, Ind., Feb 25, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Zimmer Holdings, Inc. (NYSE: ZMH; SWX: ZMH), a leader in the orthopaedic industry, today announced that an interactive Trabecular Metal(TM) Technology experience will be among the highlights of the Company's presence at the 76th annual American Academy of Orthopaedic Surgeons (AAOS) meeting in Las Vegas. During AAOS 2009, Zimmer will showcase a number of new product launches that span the Company's portfolio, and The Zimmer Institute will host presentations at an on-site education theater.

"We've always considered the Academy meeting to be a great place to showcase our products and technologies, and an unmatched forum for interacting with surgeons and researchers from around the world," said David Dvorak, President and CEO of Zimmer Holdings. "This year we're particularly excited to present an interactive environment for surgeons to explore our Trabecular Metal technology, as well as a series of presentations in our on-site Zimmer Institute theater."

Highlights of Zimmer's activities at the AAOS meeting include:

- The Trabecular Metal Technology experience on the second floor of the Zimmer exhibit will provide guests with an interactive environment to explore the structure, function and physiology of the only tantalum-engineered porous implant material. Exclusive to Zimmer, Trabecular Metal Technology is supported by more than 11 years of clinical experience. The material replicates the structure of cancellous bone more closely than other implant materials and is conducive to more normal bone formation and bone in-growth.
- The Zimmer Institute will be hosting an on-site theater and sawbones laboratory sessions featuring presentations on a number of Zimmer products, including the Zimmer(R) Gender Solutions(TM) Patello-Femoral Joint System; the M/L Taper Hip Stem with Kinectiv(R) Technology; the NexGen(R) LPS-Flex and LPS-Mobile Bearing Knee; and the Zimmer(R)

Natural Nail system.

-- A variety of new product launches that span Zimmer's product portfolio will be displayed, including DeNovo(R) NT Natural Tissue Graft for the treatment of focal cartilage defects in a variety of anatomic locations; the Zimmer Natural Nail system, which features anatomic-shaped implants designed to match the normal anatomy of long bones and achieve excellent fixation; the Zimmer(R) Periarticular Elbow Locking Plate System, which offers anatomically contoured plates, optimized screw positions and options to address most fracture types; and the exciting new Trabecular Metal Glenoid, the only glenoid component with Zimmer's exclusive porous technology for biological fixation.

"We're bullish about our industry and are confident surgeons will continue to embrace Zimmer's unique technology platforms," said Mr. Dvorak. "Zimmer remains focused on designing best-in-class products for surgeons to address patient needs. We're sure the products on display at AAOS will play a key role in enabling positive clinical outcomes in the future."

At the AAOS meeting, Zimmer will occupy exhibit 4228 from Wednesday, February 25 through Friday, February 28. The Zimmer Institute on-site theater will also host presentations during those days.

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries. Zimmer's 2008 sales were approximately \$4.1 billion. The Company is supported by the efforts of approximately 8,500 employees worldwide.

For more information about Zimmer, visit www.zimmer.com

Zimmer Safe Harbor Statement

This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management's beliefs and assumptions made by management. Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," and "seeks" or the negative of such terms or other variations on such terms or comparable terminology. These statements are not guarantees of future performance and involve

risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially. These risks and uncertainties include, but are not limited to, our compliance with the Deferred Prosecution Agreement through March 2009 and the Corporate Integrity Agreement through 2012; the impact of our enhanced healthcare compliance global initiatives and business practices on our relationships with customers and consultants, our market share and our overall financial performance; the success of our quality initiatives; the outcome of the informal investigation by the U.S. Securities and Exchange Commission into Foreign Corrupt Practices Act matters announced in October 2007; price and product competition; changes in customer demand for our products and services caused by demographic changes or other factors; dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of our products and services; supply and prices of raw materials and products; control of costs and expenses; our ability to obtain and maintain adequate intellectual property protection; our ability to successfully integrate acquired businesses; our ability to form and implement alliances; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration and foreign government regulators and tax obligations and risks; the impact of temporarily suspending U.S. distribution of one of our key hip replacement products; product liability and intellectual property litigation losses; reductions in reimbursement levels from third-party payors and cost-containment efforts of healthcare purchasing organizations; our ability to retain the independent agents and distributors who market our products; changes in general industry and market conditions, including domestic and international growth rates and general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations; and the costs of defending or resolving putative class action securities litigation and lawsuits, investigations or other proceedings resulting from our September 2007 settlement with the U.S. government and other matters. For a further list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this document.

SOURCE Zimmer Holdings, Inc.

<http://www.zimmer.com>

Copyright (C) 2009 PR Newswire. All rights reserved

